10109752Proof of concept evaluation for a novel paediatric osteosarcoma therapeuticClosedCollaborative R&DInnovate UKAnnexin-A1 is a protein that is overproduced by many tumours and plays a key role in various cancer-related processes including tumour growth, angiogenesis, drug resistance and metastasis. Medannex has generated an antibody (MDX-124) that specifically targets and blocks the cancer promoting activity of annexin-A1\. This project is a vital step in the development of an innovative paediatric cancer therapy with the strong potential to improve patient outcomes in osteosarcoma.